Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE.

Publisher: Springer Country of Publication: Italy NLM ID: 9012268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1724-6059 (Electronic) Linking ISSN: 11218428 NLM ISO Abbreviation: J Nephrol Subsets: MEDLINE

Publication: 2014- : Heidelberg : Springer
Original Publication: Rome : Acta Medica,

Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetic Nephropathies*/drug therapy ; Diabetic Nephropathies*/prevention & control ; Sodium-Glucose Transporter 2 Inhibitors*/adverse effects; Humans ; Kidney ; Sodium-Glucose Transporter 2

The burden of diabetic kidney disease is rising rapidly worldwide, and new therapies are of vital importance to reduce the risk of kidney failure and major cardiovascular events. Of the newer glucose-lowering agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown exciting potential in preventing these adverse events. The results of several large cardiovascular outcome trials, a single dedicated kidney outcome trial and a dedicated heart failure trial, demonstrate substantial clinical benefits for several different SGLT2 inhibitors. Emerging evidence raises the possibility that these benefits may extend to those with non-diabetic chronic kidney disease. This review summarises the current evidence for SGLT2 inhibitor benefits and harms, and examines which patients are most likely to gain from these therapies.

Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M et al (2020) Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395:709–733. (PMID: 10.1016/S0140-6736(20)30045-3)
Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Barnighausen T et al (2017) The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 5(6):423–430. (PMID: 10.1016/S2213-8587(17)30097-9)
Astor BC, Matsushita K, Gansevoort RT, Van Der Velde M, Woodward M, Levey AS et al (2011) Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 79(12):1331–1340. (PMID: 10.1038/ki.2010.55021289598)
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329(20):1456–1462. (PMID: 10.1056/NEJM199311113292004)
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860. (PMID: 10.1056/NEJMoa011303)
Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869. (PMID: 10.1056/NEJMoa011161)
Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME et al (2016) Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39(5):694–700. (PMID: 10.2337/dc15-232227006512)
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2(5):369–384. (PMID: 10.1016/S2213-8587(13)70208-024795251)
Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L et al (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15(5):463–473. (PMID: 10.1111/dom.1209023464594)
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375(9733):2223–2233. (PMID: 10.1016/S0140-6736(10)60407-2)
Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V (2017) Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28(1):368–375. (PMID: 10.1681/ASN.2016030278)
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Eng J Med 375(4):323–334. (PMID: 10.1056/NEJMoa1515920)
Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Eng J Med 377(7):644–657. (PMID: 10.1056/NEJMoa1611925)
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Eng J Med 380(4):347–357. (PMID: 10.1056/NEJMoa1812389)
Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5(8):610–621. (PMID: 10.1016/S2213-8587(17)30182-1)
Raz I, Wiviott SD, Yanuv I, Rozenberg A, Zelniker TA, Cahn A et al (2019) Effects of dapagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes: a predefined analysis from the declare-timi 58 randomised, placebo-controlled trial. Diabetes Conference: 79th Scientific Sessions of the American Diabetes Association, ADA. 68(Supplement 1).
Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845–854. (PMID: 10.1016/S2213-8587(19)30256-6)
Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM et al (2018) The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46(6):462–472. (PMID: 10.1159/000484633)
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306. (PMID: 10.1056/NEJMoa181174430990260)
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008. (PMID: 10.1056/NEJMoa191130331535829)
McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM et al (2019) The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 21(11):1402–1411. (PMID: 10.1002/ejhf.154831309699)
Merck announces first-quarter 2020 financial results (press release). Kenilworth NJ, Mercke, 28 April 2020.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339–352. (PMID: 10.1016/S0140-6736(13)60595-4)
Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731):2073–2081. (PMID: 10.1016/S0140-6736(10)60674-53993088)
Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP et al (2020) Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc 9(3):e014908. (PMID: 10.1161/JAHA.119.01490831992158)
Neuen BL, Ohkuma T, Neal B, Matthews DR, De Zeeuw D, Mahaffey KW et al (2019) Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol 30(11):2229–2242. (PMID: 10.1681/ASN.201901006431530577)
Radholm K, Zhou Z, Clemens K, Neal B, Woodward M (2020) Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab 22(2):263–266. (PMID: 10.1111/dom.1387631486272)
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31–39. (PMID: 10.1016/S0140-6736(18)32590-X)
Neuen BL, Cherney DZ, Jardine MJ, Perkovic V (2019) Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. Can Med Assoc J 191(41):E1128–E1135. (PMID: 10.1503/cmaj.190047)
Liu J, Li L, Li S, Jia P, Deng K, Chen W et al (2017) Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep 7(1):2824. (PMID: 10.1038/s41598-017-02733-w5460243)
Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134(10):752–772. (PMID: 10.1161/CIRCULATIONAHA.116.021887)
Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC et al (2020) SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci 5(2):169–179. (PMID: 10.1016/j.jacbts.2019.11.0077046513)
Kiuchi S, Hisatake S, Kabuki T, Fujii T, Oka T, Dobashi S et al (2018) Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: a case report. Drug Discov Ther 12(1):51–54. (PMID: 10.5582/ddt.2017.01069)
Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94(1):26–39. (PMID: 10.1016/j.kint.2017.12.027)
Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T et al (2018) A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int 94(3):524–535. (PMID: 10.1016/j.kint.2018.05.002)
Kashihara N, Kidokoro K, Kanda E (2020) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms. Curr Opin Nephrol Hypertens 29(1):112–118. (PMID: 10.1097/MNH.0000000000000561)

Keywords: Chronic kidney disease; Clinical outcomes; SGLT2 inhibitors; Type 2 diabetes

0 (Sodium-Glucose Transporter 2)
0 (Sodium-Glucose Transporter 2 Inhibitors)

Date Created: 20200730 Date Completed: 20210818 Latest Revision: 20211112

20231215

10.1007/s40620-020-00809-x

32725496